Synopsis

Real-world evidence concerning the use of prescription treatments for opioid-induced constipation (OIC) in the emergency department (ED) is lacking. This retrospective analysis compared healthcare resource utilization in hospitals and healthcare costs among patients reporting to the ED who received OIC treatment (n=11,135, 93% used methylnaltrexone SC) versus those who did not (n=21, 474). Overall, patients who received prescription OIC treatment were more likely to be discharged home, less likely to be hospitalized, had a reduced hospital stay, and a mean of $1152 less in total healthcare costs per ED encounter than patients who did not receive prescription OIC treatment.

Disclosures

WFP has received research grants from Abbott, Boehringer Ingelheim, Braincheck, CSL Behring, Daiichi-Sankyo, ImmunArray, Janssen, Ortho Clinical Diagnostics, Portola, Relypsa, and Roche. He serves as a consultant for Abbott, AstraZeneca, Bayer, Beckman, Boehringer Ingelheim, Ischemia Care, LLC, ImmunArray, Instrument Labs, Janssen, Nabriva, Ortho Clinical Diagnostics, Relypsa, Roche, Quidel, Salix, and Siemens. He has provided expert testimony for Johnson & Johnson and has stock/ownership interests in AseptiScope Inc, Brainbox Inc, Comprehensive Research Associates LLC, Emergencies in Medicine LLC, and Ischemia Care, LLC.
NES is an employee of Salix Pharmaceuticals, a subsidiary of Bausch Health US, LLC.
PGS, JM, and AG are employees of Analysis Group, Inc., a consulting company that has provided paid consulting services to Bausch Health US, LLC., which funded the development and conduct of this study.
GJ is a full-time employee and shareholder of Bausch Health US, LLC.

Patrick Gagnon-Sanschagrin MSc

Manager, Analysis Group, Inc

Appearances